Acadian Asset Management
RPRX

Acadian Asset Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Acadian Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-26,116
Closed -$25K – 1664
2016
Q1 		$25K Hold
26,116
– – ﹤0.01% 1107
2015
Q4 		$32K Buy
+26,116
New +$83.8K ﹤0.01% 1147

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Acadian Asset Management's RPRX Position: Q2 2016 in Review

Acadian Asset Management sold out of Repros Therapeutics Inc. (RPRX) in Q2 2016, closing a stake of 26,116 shares — an estimated $25K sold.

Acadian Asset Management first reported a position in RPRX in Q4 2015 and held it in 2 quarters. The position peaked at $32K in Q4 2015. 43 funds tracked by Wall St. Rank hold RPRX as of Q2 2016.

  • Acadian Asset Management reported no remaining Repros Therapeutics Inc. position as of Q2 2016 after selling out during the quarter.
  • Acadian Asset Management sold 26,116 Repros Therapeutics Inc. shares in Q2 2016, an estimated $25K.
  • Acadian Asset Management first reported a position in Repros Therapeutics Inc. in Q4 2015 and held it in 2 quarters.
  • Acadian Asset Management's Repros Therapeutics Inc. position peaked at $32K in Q4 2015.
  • 43 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2016.

Based on Acadian Asset Management's 13F filing for Q2 2016, filed 19 Jul 2016.